Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070564 · ClinicalTrials.gov registry record · Phase 3
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- Phase 3
- Development phase
- 3,294
- Enrollment target
- 20
- Study locations
NCT00070564 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 3,294 participants, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00070564, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,294 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- DRUG doxorubicin hydrochloride
- BIOLOGICAL pegfilgrastim
- DRUG AC regimen
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- East Bay Radiation Oncology Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Valley Medical Oncology - Fremont
- California Cancer Center - Woodward Park Office - Fresno
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
- Memorial Medical Center - Modesto
- El Camino Hospital Cancer Center - Mountain View
Alabama
- Regional Medical Center - Anniston
- UAB Comprehensive Cancer Center - Birmingham
- Providence Cancer Center at Providence Hospital - Mobile
Arizona
- Mayo Clinic Scottsdale - Scottsdale
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Alaska
- Providence Cancer Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,294 participants |
| Start Date | 2003-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070564
The ClinicalTrials.gov registry entry for NCT00070564 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 3,294 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (18% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00070564 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00070564 about?
NCT00070564 is a clinical study titled "S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which com...
What is the current status of trial NCT00070564?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,294 participants. The study started on 2003-11. Estimated completion is 2027-01.
What conditions does trial NCT00070564 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00070564?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), doxorubicin hydrochloride (DRUG), pegfilgrastim (BIOLOGICAL), AC regimen (DRUG).
Who is sponsoring clinical trial NCT00070564?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070564 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.